Reported Monday, Daiichi Sankyo And AstraZeneca's Datopotamab Deruxtecan Show Survival Improvement Versus Chemotherapy In Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer In TROPION-Lung01 Phase 3 Trial
Reported Monday, Daiichi Sankyo And AstraZeneca's Datopotamab Deruxtecan Show Survival Improvement Versus Chemotherapy In Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer In TROPION-Lung01 Phase 3 Trial
周一报道，在Tropion-Lung01 3期试验中，第一三共和阿斯利康的Datopotamab Deruxtecan显示，与化疗相比，晚期非鳞状非小细胞肺癌患者的存活率有所改善
- In the overall trial population, survival results numerically favored Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan but did not reach statistical significance
- TROPION-Lung01 previously met the dual primary endpoint of progression-free survival in the overall trial population
- Results support applications currently under review by regulatory authorities globally including the U.S. and EU
- 在整个试验人群中，存活结果在数字上有利于第一三共和阿斯利康的datopotamab deruxtecan，但没有达到统计学意义
- Tropion-Lung01 此前在整个试验人群中达到无进展存活率的双重主要终点
- 结果支持包括美国和欧盟在内的全球监管机构目前正在审查的申请